Beschreibung
InhaltsangabeIntroduction. 1. Elements of Veterinary Pharmacovigilance. 2. Veterinary Pharmacovigilance in the European Union. 3. Pharmacovigilance and the European Medicines Agency: Conduct of Pharmacovigilance Activities. 4. Veterinary Pharmacovigilance in France. 5. Pharmacovigilance in Germany. 6. Veterinary Pharmacovigilance - the UK Experience. 7. Veterinary Adverse Drug Reporting in the United States, Australia and Canada. 8. Veterinary Pharmacovigilance: A South African Perspective. 9. Pharmacovigilance Inspections in the European Union. 10. Essential Elements of Veterinary Pharmacovigilance and the Role and Duties of the Qualified Person. 11. Veterinary Pharmacovigilance in an Industry Setting - The EU. 12. Pharmacovigilance in the US - Industry Perspective. 13. Practical Veterinary Pharmacovigilance. 14. Preclinical Safety Testing and Assessment of Veterinary Pharmaceuticals and Pharmacovigilance. 15. Safety Assessment of Veterinary Vaccines. 16. Microbiological Assessment of Veterinary Medicinal Products and Potential Adverse Effects. 17. Adverse Effects of Veterinary Pharmaceutical Products in Animals. 18. Adverse Drug Reactions in Dogs - Toxic Hepatic Responses. 19. Adverse Reactions to Vaccines. 20. Adverse Reactions in Humans Following Exposure to Veterinary Drugs. 21. Medicines Used to Control and Treat External Parasites of Sheep - Toxicology and The Phenomenon of Reported Adverse Human Responses to Organophosphorus Sheep Dips. 22. User Safety Assessment of Veterinary Medicinal Products. 23. Maximum Residue Limits. 24. Determination of Withdrawal Periods for Pharmaceutical Products Used in Food Animals. 25. Surveillance for Veterinary Residues. 26. Adverse Environmental Effects and Veterinary Medicinal Products. 27. Causality in Pharmacovigilance and Expectedness of Adverse Reactions. 28. Quantitative Aspects of Veterinary Pharmacovigilance. 29. Veterinary Adverse Reactions and Crisis Management. 30. The Role of Veterinary Pharmacovigilance in Risk Analysis and the Influence of Risk Perception on Veterinary Pharmacovigilance. 31. The Role of Quality Assurance in Veterinary Pharmacovigilance. 32. Concordance Between Results from Animal Toxicology Studies and Adverse Reactions in Animals
Autorenportrait
Dr K.N. Woodward is Director of International Regulatory Affairs at Intervet/Schering-Plough Animal Health in the UK and has been involved in veterinary pharmacovigilance for over 20 years. He was formerly the Director of Licensing at the Veterinary Medicines Directorate (VMD) in the UK. He has also worked for the Health and Safety Executive on the regulation of industrial chemicals and non-agricultural pesticides and for the Department of Health where he was Scientific Secretary to the Committee on Carcinogenicity and held responsibilities for the safety of veterinary drugs. A toxicologist, he was Chairman of the Working Group on the Safety of Residues of the Committee for Veterinary Medicinal Products (CVMP, now the Committee for Medicinal Products for Veterinary Use) for over 5 years and a member of the CVMP. He was the leader of the UK delegation to the Codex Committee on Residues of Veterinary Drugs in Food in Washington for 3 years and a member of the Joint FAO/WHO Expert Committee on Food Additives (JECFA).
Leseprobe
Leseprobe
